Does Cosentyx Affect Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to some vaccines. It suppresses T-cell activity, reducing antibody production against certain pathogens.1
Live vaccines like MMR, varicella, and oral polio are contraindicated during Cosentyx treatment due to infection risk from weakened immunity.2 Non-live vaccines show mixed results: inactivated influenza vaccine yields lower seroprotection rates (e.g., 40-60% vs. 70-90% in healthy adults), and pneumococcal vaccine responses are diminished but still protective in most patients.3
How Does It Impact Specific Vaccines?
- COVID-19 vaccines: Studies show Cosentyx patients mount adequate humoral responses to mRNA vaccines (e.g., Pfizer, Moderna), with antibody levels comparable to controls, though cellular immunity may be slightly reduced. Booster doses help maintain protection.5
- Influenza vaccine: Seroconversion drops by 20-30% in IL-17 inhibitor users; annual vaccination is still recommended.6
- Shingles (shingrix): Recommended before or during treatment; response is preserved in most cases despite modest antibody titer reductions.7
- HPV and hepatitis B: Weaker responses observed; testing post-vaccination is advised.3
Physicians often suggest vaccinating before starting Cosentyx or using higher doses/boosters for at-risk patients.
What Do Clinical Trials and Real-World Data Show?
Phase 3 trials (e.g., FUTURE and MEASURE programs) excluded live vaccines but confirmed reduced immunogenicity for tetanus toxoid and pneumococcal vaccines in Cosentyx users.4 Real-world studies, including a 2023 meta-analysis, report 10-25% lower vaccine efficacy across biologics like secukinumab, with no increased breakthrough infection rates when non-live vaccines are used.8
No patents directly address vaccine interactions on DrugPatentWatch.com, as Cosentyx patents focus on the molecule (U.S. Patent 7,807,155 expires 2027).9
Recommendations for Patients on Cosentyx
Get non-live vaccines 4-6 weeks before starting treatment if possible. Avoid live vaccines during therapy and for 4-6 weeks after stopping. Monitor titers for high-risk groups (e.g., elderly, immunocompromised). Consult rheumatologists or dermatologists for personalized plans—ACR guidelines endorse vaccination but note response variability.2
Compared to Other Biologics
| Drug | Vaccine Impact | Key Difference |
|------|---------------|---------------|
| Cosentyx (IL-17) | Moderate reduction in non-live; live contraindicated | Less B-cell suppression than TNF inhibitors |
| Humira (TNF) | Stronger impairment (e.g., 50% lower flu response) | Higher infection risk overall |
| Stelara (IL-12/23) | Similar to Cosentyx; better COVID response | Targets broader cytokines |
| Skyrizi (IL-23) | Minimal impact on most vaccines | Often preferred for vaccination needs |
TNF inhibitors like Humira pose greater risks.3
Sources